Gut Liver. 2026;20(2):266-274.

Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease.

, , , , , , ,

제1저자 전유경 · 교신저자 윤혁,황성욱

PMID 40958654 PMC12989668 DOI 10.5009/gnl250188 IF 4.1 소화기내과

소속 (3)

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS Subcutaneous (SC) vedolizumab (VDZ) has recently become available for patients with inflammatory bowel disease (IBD) in Korea. This retrospective observational study aimed to evaluate the clinical outcomes and safety of switching from intravenous (IV) to SC VDZ.

METHODS Patients with IBD who switched from IV to SC VDZ between 2023 and 2024 were included. The primary outcome was the 24-week persistence rate of SC VDZ. Secondary outcomes included clinical factors associated with SC VDZ persistence, safety profiles, subsequent treatment courses after discontinuation of SC VDZ, and recapture success rate after reverting to IV VDZ.

RESULTS A total of 101 patients with IBD (72 with ulcerative colitis [UC] and 29 with Crohn's disease) were included. After 24 weeks, 72 patients (71.3%) maintained SC VDZ. Corticosteroid use at switching was the strongest predictor of 24-week SC VDZ failure in both the overall IBD cohort (p=0.018) and in patients with UC (p=0.027) in multivariable analyses. Kaplan-Meier analysis showed that patients with UC with intensified IV dosing intervals (p=0.021), failure to clinical remission (p=0.038), or concomitant corticosteroid use at switching (p<0.001) were more likely to discontinue SC VDZ. Injection-site reactions occurred in 24 patients (23.8%). A total of 34 patients (33.7%) discontinued SC VDZ; 19 resumed IV VDZ; and 13 initiated another advanced therapy. The recapture success rate after reverting to IV VDZ was 73.7%, with higher success in those who discontinued because of injection-site reactions or poor adherence.

CONCLUSIONS SC VDZ persistence is significantly influenced by disease activity at the time of switching.

Keywords

Crohn diseaseInflammatory bowel diseaseSubcutaneous applicationUlcerative colitisVedolizumab

Figures

**Fig. 1** Kaplan-Meier curves depicting the cumulative rates of SC VDZ treatment persistence, stratified by (A) the administration interval of previous IV VDZ, (B) clinical activity at the time of switching, and (C) concomitant corticosteroid use at the time of switching. IV, intravenous; SC, subcutaneous; VDZ, vedolizumab; pMayo, partial Mayo.

그림 출처: PubMed Central 공개 논문 (PMC12989668)

Conflict of interest statement

CONFLICTS OF INTEREST . No potential conflict of interest relevant to this article was reported.

그 밖의 정보